idarubicin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, daunorubicin derivatives 1414 58957-92-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • idarubicin
  • 4-Demethoxydaunomycin
  • 4-Demethoxydaunorubicin
  • demethoxydaunorubicin
  • idarubicin hydrochloride
  • idarubicin HCl
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
  • Molecular weight: 497.50
  • Formula: C26H27NO9
  • CLOGP: 0.84
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 5
  • TPSA: 176.61
  • ALOGS: -2.81
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.43 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 28 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 38 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 24 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.08 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 16 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 10 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Sept. 27, 1990 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 578.72 38.26 252 5065 118197 63365508
Differentiation syndrome 203.08 38.26 40 5277 1063 63482642
Acute myeloid leukaemia recurrent 170.71 38.26 37 5280 1586 63482119
Fusarium infection 153.38 38.26 29 5288 617 63483088
Neutropenia 148.03 38.26 120 5197 174885 63308820
Neutropenic colitis 146.95 38.26 37 5280 3058 63480647
Geotrichum infection 136.23 38.26 25 5292 449 63483256
Thrombocytopenia 130.61 38.26 105 5212 151052 63332653
Septic shock 125.91 38.26 75 5242 66554 63417151
Mucosal inflammation 121.66 38.26 65 5252 46863 63436842
Bone marrow failure 118.77 38.26 55 5262 29235 63454470
Neoplasm recurrence 107.87 38.26 28 5289 2610 63481095
Acute myeloid leukaemia 104.77 38.26 43 5274 17104 63466601
Multiple organ dysfunction syndrome 102.30 38.26 62 5255 56690 63427015
Pancytopenia 95.85 38.26 73 5244 96860 63386845
Sepsis 90.99 38.26 86 5231 153037 63330668
Leukaemia recurrent 83.84 38.26 20 5297 1318 63482387
Myelosuppression 82.25 38.26 40 5277 23663 63460042
Second primary malignancy 81.18 38.26 29 5288 7924 63475781
Acute lymphocytic leukaemia recurrent 73.35 38.26 20 5297 2249 63481456
Bronchopulmonary aspergillosis 64.35 38.26 25 5292 8610 63475095
Febrile bone marrow aplasia 61.02 38.26 23 5294 7302 63476403
Gene mutation 60.05 38.26 16 5301 1649 63482056
Neurotoxicity 59.92 38.26 29 5288 16961 63466744
Haemophagocytic lymphohistiocytosis 59.33 38.26 25 5292 10602 63473103
Disseminated intravascular coagulation 56.77 38.26 29 5288 19022 63464683
Endophthalmitis 55.98 38.26 18 5299 3574 63480131
Lower respiratory tract infection fungal 54.60 38.26 11 5306 328 63483377
Pneumonia fungal 52.32 38.26 19 5298 5436 63478269
Ventricular hypokinesia 47.63 38.26 17 5300 4627 63479078
Mucormycosis 47.26 38.26 15 5302 2856 63480849
Ejection fraction decreased 47.01 38.26 27 5290 22305 63461400
Dedifferentiated liposarcoma 45.54 38.26 7 5310 39 63483666
Aspergillus infection 45.04 38.26 19 5298 8074 63475631
Neutropenic sepsis 43.19 38.26 23 5294 16415 63467290
Myelodysplastic syndrome 42.77 38.26 23 5294 16731 63466974
Hyperbilirubinaemia 41.98 38.26 20 5297 11294 63472411
Fungaemia 41.40 38.26 13 5304 2390 63481315
Cytarabine syndrome 40.93 38.26 7 5310 82 63483623
Cytomegalovirus infection 40.58 38.26 24 5293 20928 63462777
Pain 40.04 38.26 7 5310 740621 62743084
Leukoerythroblastosis 39.95 38.26 8 5309 231 63483474
Product use in unapproved indication 39.78 38.26 61 5256 179019 63304686
Chromosomal deletion 39.51 38.26 7 5310 102 63483603
Neutropenic infection 39.34 38.26 11 5306 1356 63482349
Haematopoietic neoplasm 38.52 38.26 6 5311 37 63483668

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 496.28 29.85 309 6146 136540 34813936
Neutropenia 163.24 29.85 171 6284 156607 34793869
Acute myeloid leukaemia recurrent 158.60 29.85 43 6412 2127 34948349
Bronchopulmonary aspergillosis 141.44 29.85 64 6391 14595 34935881
Fungal infection 124.10 29.85 60 6395 15875 34934601
Differentiation syndrome 121.68 29.85 32 6423 1406 34949070
Bone marrow failure 112.49 29.85 69 6386 29184 34921292
Mucormycosis 101.47 29.85 39 6416 5903 34944573
Acute myeloid leukaemia 93.79 29.85 52 6403 18218 34932258
Myelodysplastic syndrome 88.68 29.85 51 6404 19157 34931319
Septic shock 88.43 29.85 86 6369 71748 34878728
Pancytopenia 85.07 29.85 96 6359 95061 34855415
Aspergillus infection 77.27 29.85 40 6415 12214 34938262
Venoocclusive liver disease 74.33 29.85 34 6421 7932 34942544
Thrombocytopenia 72.06 29.85 114 6341 156133 34794343
Fusarium infection 70.98 29.85 20 6435 1140 34949336
Neutropenic colitis 69.69 29.85 25 6430 3119 34947357
Pneumonia fungal 62.17 29.85 29 6426 7071 34943405
Febrile bone marrow aplasia 61.14 29.85 30 6425 8179 34942297
Sepsis 58.87 29.85 108 6347 166453 34784023
Aeromonas infection 58.73 29.85 13 6442 271 34950205
Cytomegalovirus infection reactivation 54.62 29.85 24 6431 5094 34945382
Myelosuppression 50.96 29.85 36 6419 19229 34931247
Stenotrophomonas infection 47.60 29.85 17 6438 2093 34948383
Second primary malignancy 47.58 29.85 25 6430 7861 34942615
Neoplasm progression 47.00 29.85 37 6418 23263 34927213
Geotrichum infection 46.42 29.85 12 6443 492 34949984
Mucosal inflammation 45.14 29.85 45 6410 38577 34911899
Pyrexia 42.30 29.85 146 6309 332867 34617609
Chronic graft versus host disease 41.84 29.85 19 6436 4354 34946122
Product use in unapproved indication 39.94 29.85 75 6380 117424 34833052
Haematopoietic neoplasm 38.64 29.85 7 6448 49 34950427
Adenomatous polyposis coli 36.85 29.85 8 6447 152 34950324
Poikiloderma 35.73 29.85 8 6447 176 34950300
Neoplasm recurrence 35.68 29.85 14 6441 2235 34948241
Premature ageing 35.56 29.85 7 6448 80 34950396
Rhabdomyosarcoma recurrent 33.86 29.85 7 6448 104 34950372
Drug resistance 33.64 29.85 32 6423 25895 34924581
T-cell type acute leukaemia 32.81 29.85 7 6448 122 34950354
Myocarditis 32.59 29.85 24 6431 13658 34936818
Reticulocytosis 32.39 29.85 8 6447 272 34950204
Hyperbilirubinaemia 32.36 29.85 26 6429 16817 34933659
Infection 30.83 29.85 58 6397 90857 34859619
Recurrent cancer 30.63 29.85 11 6444 1376 34949100
Escherichia bacteraemia 30.59 29.85 14 6441 3266 34947210
Acute graft versus host disease in skin 29.99 29.85 16 6439 5185 34945291

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 1002.63 25.81 539 11038 230460 79502351
Differentiation syndrome 298.25 25.81 70 11507 2454 79730357
Neutropenia 276.05 25.81 269 11308 287441 79445370
Acute myeloid leukaemia recurrent 248.34 25.81 64 11513 3319 79729492
Fusarium infection 243.99 25.81 56 11521 1776 79731035
Neutropenic colitis 219.57 25.81 65 11512 5642 79727169
Bone marrow failure 219.19 25.81 119 11458 50988 79681823
Septic shock 203.22 25.81 157 11420 122644 79610167
Acute myeloid leukaemia 187.75 25.81 91 11486 30794 79702017
Pancytopenia 185.40 25.81 169 11408 165576 79567235
Bronchopulmonary aspergillosis 176.89 25.81 79 11498 22215 79710596
Thrombocytopenia 175.82 25.81 204 11373 265055 79467756
Myelodysplastic syndrome transformation 170.17 25.81 35 11542 654 79732157
Geotrichum infection 168.92 25.81 37 11540 944 79731867
Fungal infection 137.91 25.81 82 11495 41666 79691145
Second primary malignancy 137.16 25.81 58 11519 14292 79718519
Myelodysplastic syndrome 125.52 25.81 69 11508 30232 79702579
Sepsis 124.11 25.81 173 11404 269255 79463556
Mucosal inflammation 121.34 25.81 95 11482 75485 79657326
Myelosuppression 114.78 25.81 72 11505 40224 79692587
Pneumonia fungal 112.78 25.81 47 11530 11163 79721648
Neoplasm recurrence 111.36 25.81 36 11541 4178 79728633
Mucormycosis 111.15 25.81 43 11534 8426 79724385
Aspergillus infection 106.09 25.81 53 11524 19108 79713703
Venoocclusive liver disease 94.26 25.81 42 11535 11729 79721082
Febrile bone marrow aplasia 87.11 25.81 41 11536 12979 79719832
Multiple organ dysfunction syndrome 85.37 25.81 96 11481 120150 79612661
Acute lymphocytic leukaemia recurrent 76.58 25.81 28 11549 4696 79728115
Haematopoietic neoplasm 76.19 25.81 13 11564 81 79732730
Hyperbilirubinaemia 72.80 25.81 45 11532 24473 79708338
Pain 71.69 25.81 9 11568 703793 79029018
Product use in unapproved indication 71.13 25.81 129 11448 250230 79482581
Leukaemia recurrent 70.46 25.81 23 11554 2751 79730060
Stenotrophomonas infection 67.29 25.81 24 11553 3749 79729062
Pyrexia 62.55 25.81 228 11349 678481 79054330
Fungaemia 59.14 25.81 23 11554 4568 79728243
Drug resistance 59.07 25.81 49 11528 42164 79690647
Aeromonas infection 58.21 25.81 13 11564 363 79732448
Neoplasm progression 58.21 25.81 53 11524 51629 79681182
Haemophagocytic lymphohistiocytosis 57.13 25.81 37 11540 21800 79711011
Myocarditis 54.84 25.81 36 11541 21697 79711114
Arthralgia 54.25 25.81 9 11568 571794 79161017
Pathogen resistance 52.15 25.81 30 11547 14312 79718499
Bacteraemia 52.06 25.81 41 11536 32783 79700028
Dizziness 50.58 25.81 8 11569 526433 79206378
Pneumonia 50.33 25.81 209 11368 660037 79072774
Neutropenic infection 49.26 25.81 17 11560 2410 79730401
Fatigue 49.22 25.81 38 11539 929689 78803122
Disseminated intravascular coagulation 48.89 25.81 41 11536 35801 79697010
Cytarabine syndrome 48.36 25.81 9 11568 97 79732714
Cytomegalovirus infection reactivation 47.91 25.81 24 11553 8692 79724119
Fall 47.77 25.81 7 11570 487622 79245189
Cytomegalovirus infection 46.59 25.81 43 11534 42601 79690210
Respiratory failure 46.05 25.81 89 11488 180822 79551989
Dysplasia 45.60 25.81 14 11563 1372 79731439
Ventricular hypokinesia 43.63 25.81 23 11554 9256 79723555
Graft versus host disease 43.14 25.81 27 11550 14999 79717812
Lower respiratory tract infection fungal 42.54 25.81 12 11565 876 79731935
Acute respiratory distress syndrome 41.61 25.81 41 11536 44026 79688785
Tumour lysis syndrome 40.35 25.81 31 11546 23908 79708903
Escherichia bacteraemia 38.83 25.81 19 11558 6543 79726268
Rash maculo-papular 38.44 25.81 44 11533 56034 79676777
Ejection fraction decreased 38.03 25.81 35 11542 34542 79698269
Premature ageing 36.77 25.81 7 11570 86 79732725
Infective aneurysm 36.67 25.81 11 11566 997 79731814
Recurrent cancer 36.49 25.81 14 11563 2679 79730132
Pulmonary haemorrhage 36.21 25.81 24 11553 14693 79718118
Cytopenia 35.68 25.81 27 11550 20356 79712455
Chronic graft versus host disease 35.31 25.81 18 11559 6763 79726048
Adenomatous polyposis coli 35.20 25.81 8 11569 242 79732569
Chloroma 35.05 25.81 10 11567 760 79732051
Weight decreased 34.99 25.81 5 11572 355193 79377618
Enterococcal bacteraemia 34.72 25.81 14 11563 3054 79729757
Haemorrhagic pneumonia 33.97 25.81 7 11570 132 79732679
Leukoerythroblastosis 33.44 25.81 8 11569 304 79732507
Aplasia 32.89 25.81 18 11559 7802 79725009
Chromosomal deletion 32.64 25.81 7 11570 161 79732650
Streptococcal bacteraemia 32.54 25.81 14 11563 3592 79729219
Colitis 32.03 25.81 46 11531 73261 79659550
T-cell type acute leukaemia 31.75 25.81 7 11570 184 79732627
Hidradenitis 31.41 25.81 13 11564 3031 79729780
Poikiloderma 31.41 25.81 8 11569 395 79732416
Cardiomyopathy 31.40 25.81 29 11548 28745 79704066
Malaise 31.38 25.81 16 11561 489853 79242958
Acute graft versus host disease in skin 30.49 25.81 17 11560 7641 79725170
Reticulocytosis 29.55 25.81 8 11569 501 79732310
Gamma-glutamyltransferase increased 29.48 25.81 38 11539 54642 79678169
Pleural effusion 29.34 25.81 65 11512 145197 79587614
Peripheral swelling 28.49 25.81 3 11574 269614 79463197
Necrotising fasciitis 28.45 25.81 15 11562 6035 79726776
Neurotoxicity 28.39 25.81 29 11548 32489 79700322
Dyspnoea 28.17 25.81 51 11526 856974 78875837
Haematotoxicity 28.15 25.81 21 11556 15498 79717313
Pharyngeal inflammation 28.03 25.81 9 11568 1021 79731790
Anti-platelet antibody positive 28.03 25.81 7 11570 319 79732492
Posterior reversible encephalopathy syndrome 27.73 25.81 26 11551 26255 79706556
Endophthalmitis 27.60 25.81 15 11562 6413 79726398
Cytogenetic abnormality 27.25 25.81 9 11568 1116 79731695
Philadelphia chromosome positive 27.15 25.81 8 11569 682 79732129
Large granular lymphocytosis 26.91 25.81 7 11570 376 79732435
Blood bilirubin increased 26.68 25.81 40 11537 66192 79666619
Pseudomonas infection 26.64 25.81 23 11554 20880 79711931
Primary hypogonadism 26.42 25.81 6 11571 181 79732630
Pain in extremity 26.34 25.81 10 11567 364528 79368283
Raoultella ornithinolytica infection 26.30 25.81 5 11572 61 79732750
Pericardial effusion 26.30 25.81 33 11544 46204 79686607
Gene mutation 26.13 25.81 11 11566 2675 79730136
Coombs direct test positive 26.09 25.81 7 11570 424 79732387
Abdominal discomfort 25.96 25.81 3 11574 250724 79482087
Leukaemia 25.92 25.81 14 11563 5911 79726900
Leukaemia cutis 25.90 25.81 6 11571 198 79732613

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DB06 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Anthracyclines and related substances
FDA CS M0028312 Anthracyclines
FDA MoA N0000000176 Topoisomerase Inhibitors
FDA EPC N0000175414 Anthracycline Topoisomerase Inhibitor
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D059005 Topoisomerase II Inhibitors
MeSH PA D059003 Topoisomerase Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute myeloid leukemia, disease indication 91861009
Acute promyelocytic leukemia, FAB M3 indication 110004001
Pericarditis contraindication 3238004 DOID:1787
Enterocolitis contraindication 43752006
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Myocarditis contraindication 50920009 DOID:820
Gastrointestinal perforation contraindication 51875005
Acute infectious disease contraindication 63171007
Cardiomyopathy contraindication 85898001 DOID:0050700
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.01 acidic
pKa2 9.88 acidic
pKa3 11.6 acidic
pKa4 8.73 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase 2-alpha Enzyme INHIBITOR WOMBAT-PK CHEMBL
Multidrug resistance protein 1 Transporter WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK

External reference:

IDSource
4019784 VUID
N0000147874 NUI
D01747 KEGG_DRUG
57852-57-0 SECONDARY_CAS_RN
4019569 VANDF
4019784 VANDF
C0020789 UMLSCUI
CHEBI:42068 CHEBI
DM5 PDB_CHEM_ID
CHEMBL1117 ChEMBL_ID
CHEMBL1200976 ChEMBL_ID
D015255 MESH_DESCRIPTOR_UI
DB01177 DRUGBANK_ID
7083 IUPHAR_LIGAND_ID
5174 INN_ID
ZRP63D75JW UNII
42890 PUBCHEM_CID
5650 RXNORM
45101 MMSL
4865 MMSL
d00256 MMSL
003556 NDDF
004819 NDDF
108786002 SNOMEDCT_US
108788001 SNOMEDCT_US
372539000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Idamycin PFS HUMAN PRESCRIPTION DRUG LABEL 1 0013-2576 SOLUTION 1 mg INTRAVENOUS NDA 24 sections
Idamycin PFS HUMAN PRESCRIPTION DRUG LABEL 1 0013-2576 SOLUTION 1 mg INTRAVENOUS NDA 24 sections
Idamycin PFS HUMAN PRESCRIPTION DRUG LABEL 1 0013-2576 SOLUTION 1 mg INTRAVENOUS NDA 24 sections
Idamycin PFS HUMAN PRESCRIPTION DRUG LABEL 1 0013-2586 SOLUTION 1 mg INTRAVENOUS NDA 24 sections
Idamycin PFS HUMAN PRESCRIPTION DRUG LABEL 1 0013-2586 SOLUTION 1 mg INTRAVENOUS NDA 24 sections
Idamycin PFS HUMAN PRESCRIPTION DRUG LABEL 1 0013-2586 SOLUTION 1 mg INTRAVENOUS NDA 24 sections
Idamycin PFS HUMAN PRESCRIPTION DRUG LABEL 1 0013-2596 SOLUTION 1 mg INTRAVENOUS NDA 24 sections
Idamycin PFS HUMAN PRESCRIPTION DRUG LABEL 1 0013-2596 SOLUTION 1 mg INTRAVENOUS NDA 24 sections
Idamycin PFS HUMAN PRESCRIPTION DRUG LABEL 1 0013-2596 SOLUTION 1 mg INTRAVENOUS NDA 24 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9217 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9217 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9218 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9218 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9219 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9219 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9306 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9307 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9308 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-4154 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-4154 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-4154 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-4155 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-4155 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-4155 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-4156 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-4156 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections
Idarubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-4156 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 23 sections